Gyroscope Capital Management Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Gyroscope Capital Management Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-7,681	Closed	-$933K	–	108
2016 Q3	$933K	Hold	7,681	–	–	0.7%	35
2016 Q2	$1.08M	Hold	7,681	–	–	0.88%	31
2016 Q1	$1M	Hold	7,681	–	–	0.77%	33
2015 Q4	$1.08M	Buy	+7,681	New	+$1.06M	0.85%	33

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Gyroscope Capital Management Group's JAZZ Position: Q4 2016 in Review

Gyroscope Capital Management Group sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2016, closing a stake of 7,681 shares — an estimated $933K sold.

Gyroscope Capital Management Group first reported a position in JAZZ in Q4 2015 and held it in 4 quarters. The position peaked at $1.08M in Q2 2016. 295 funds tracked by Wall St. Rank hold JAZZ as of Q4 2016.

Gyroscope Capital Management Group reported no remaining Jazz Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Gyroscope Capital Management Group sold 7,681 Jazz Pharmaceuticals shares in Q4 2016, an estimated $933K.
Gyroscope Capital Management Group first reported a position in Jazz Pharmaceuticals in Q4 2015 and held it in 4 quarters.
Gyroscope Capital Management Group's Jazz Pharmaceuticals position peaked at $1.08M in Q2 2016.
295 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2016.

Based on Gyroscope Capital Management Group's 13F filing for Q4 2016, filed 13 Feb 2017.